ITP is Classified Under Hematology
Immune thrombocytopenia (ITP) is definitively a hematologic disorder, not a rheumatologic condition. The American Society of Hematology (ASH) has published the authoritative evidence-based practice guidelines for ITP diagnosis and management, establishing it firmly within the domain of hematology 1, 2.
Why Hematology?
ITP is fundamentally a blood disorder characterized by isolated thrombocytopenia (low platelet count) resulting from:
- Immune-mediated platelet destruction
- Impaired platelet production by bone marrow
- Abnormalities in platelet homeostasis 1, 3
The disease involves platelets and bone marrow function—core hematologic concerns—rather than systemic inflammatory joint or connective tissue manifestations typical of rheumatologic diseases.
The Rheumatology Connection (Secondary ITP)
While ITP is managed by hematologists, there is an important overlap with rheumatology when ITP occurs secondary to autoimmune conditions:
- Secondary ITP can develop in patients with:
In these cases, the underlying rheumatologic condition is managed by rheumatology, but the ITP itself remains a hematologic complication requiring hematologic expertise 4.
Clinical Practice Implications
Primary ITP (occurring without other conditions):
- Diagnosed and managed exclusively by hematology
- Treatment includes corticosteroids, IVIg, thrombopoietin receptor agonists, rituximab, and splenectomy 2, 6
Secondary ITP (associated with autoimmune diseases):
- Requires collaborative care between hematology and rheumatology
- Hematology manages the thrombocytopenia
- Rheumatology treats the underlying autoimmune condition 4, 5
The definitive answer: ITP belongs to hematology, with rheumatology involvement only when it occurs as a secondary manifestation of connective tissue disease.